Full text
PDF





Selected References
These references are in PubMed. This may not be the complete list of references from this article.
- Ball S. P., Johnson K. J. The genetics of malignant hyperthermia. J Med Genet. 1993 Feb;30(2):89–93. doi: 10.1136/jmg.30.2.89. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Brandt N. R., Caswell A. H., Brunschwig J. P., Kang J. J., Antoniu B., Ikemoto N. Effects of anti-triadin antibody on Ca2+ release from sarcoplasmic reticulum. FEBS Lett. 1992 Mar 24;299(1):57–59. doi: 10.1016/0014-5793(92)80100-u. [DOI] [PubMed] [Google Scholar]
- Ellis F. R., Harriman D. G. A new screening test for susceptibility to malignant hyperpyrexia. Br J Anaesth. 1973 Jun;45(6):638–638. [PubMed] [Google Scholar]
- Fujii J., Otsu K., Zorzato F., de Leon S., Khanna V. K., Weiler J. E., O'Brien P. J., MacLennan D. H. Identification of a mutation in porcine ryanodine receptor associated with malignant hyperthermia. Science. 1991 Jul 26;253(5018):448–451. doi: 10.1126/science.1862346. [DOI] [PubMed] [Google Scholar]
- Halsall P. J., Cain P. A., Ellis F. R. Retrospective analysis of anaesthetics received by patients before susceptibility to malignant hyperpyrexia was recognized. Br J Anaesth. 1979 Oct;51(10):949–954. doi: 10.1093/bja/51.10.949. [DOI] [PubMed] [Google Scholar]
- Hopkins P. M., Ellis F. R., Halsall P. J., Stewart A. D. An analysis of the predictive probability of the in vitro contracture test for determining susceptibility to malignant hyperthermia. Anesth Analg. 1997 Mar;84(3):648–656. doi: 10.1097/00000539-199703000-00034. [DOI] [PubMed] [Google Scholar]
- Iles D. E., Lehmann-Horn F., Scherer S. W., Tsui L. C., Olde Weghuis D., Suijkerbuijk R. F., Heytens L., Mikala G., Schwartz A., Ellis F. R. Localization of the gene encoding the alpha 2/delta-subunits of the L-type voltage-dependent calcium channel to chromosome 7q and analysis of the segregation of flanking markers in malignant hyperthermia susceptible families. Hum Mol Genet. 1994 Jun;3(6):969–975. doi: 10.1093/hmg/3.6.969. [DOI] [PubMed] [Google Scholar]
- Kalow W., Britt B. A., Terreau M. E., Haist C. Metabolic error of muscle metabolism after recovery from malignant hyperthermia. Lancet. 1970 Oct 31;2(7679):895–898. doi: 10.1016/s0140-6736(70)92069-6. [DOI] [PubMed] [Google Scholar]
- Kawasaki T., Kasai M. Regulation of calcium channel in sarcoplasmic reticulum by calsequestrin. Biochem Biophys Res Commun. 1994 Mar 30;199(3):1120–1127. doi: 10.1006/bbrc.1994.1347. [DOI] [PubMed] [Google Scholar]
- Kreuder J., Borkhardt A., Repp R., Pekrun A., Göttsche B., Gottschalk U., Reichmann H., Schachenmayr W., Schlegel K., Lampert F. Brief report: inherited metabolic myopathy and hemolysis due to a mutation in aldolase A. N Engl J Med. 1996 Apr 25;334(17):1100–1104. doi: 10.1056/NEJM199604253341705. [DOI] [PubMed] [Google Scholar]
- Lambert C., Blanloeil Y., Horber R. K., Bérard L., Reyford H., Pinaud M. Malignant hyperthermia in a patient with hypokalemic periodic paralysis. Anesth Analg. 1994 Nov;79(5):1012–1014. doi: 10.1213/00000539-199411000-00034. [DOI] [PubMed] [Google Scholar]
- Lynch P. J., Krivosic-Horber R., Reyford H., Monnier N., Quane K., Adnet P., Haudecoeur G., Krivosic I., McCarthy T., Lunardi J. Identification of heterozygous and homozygous individuals with the novel RYR1 mutation Cys35Arg in a large kindred. Anesthesiology. 1997 Mar;86(3):620–626. doi: 10.1097/00000542-199703000-00014. [DOI] [PubMed] [Google Scholar]
- MacLennan D. H., Duff C., Zorzato F., Fujii J., Phillips M., Korneluk R. G., Frodis W., Britt B. A., Worton R. G. Ryanodine receptor gene is a candidate for predisposition to malignant hyperthermia. Nature. 1990 Feb 8;343(6258):559–561. doi: 10.1038/343559a0. [DOI] [PubMed] [Google Scholar]
- McPherson E. W., Taylor C. A., Jr The King syndrome: malignant hyperthermia, myopathy, and multiple anomalies. Am J Med Genet. 1981;8(2):159–165. doi: 10.1002/ajmg.1320080206. [DOI] [PubMed] [Google Scholar]
- Monnier N., Procaccio V., Stieglitz P., Lunardi J. Malignant-hyperthermia susceptibility is associated with a mutation of the alpha 1-subunit of the human dihydropyridine-sensitive L-type voltage-dependent calcium-channel receptor in skeletal muscle. Am J Hum Genet. 1997 Jun;60(6):1316–1325. doi: 10.1086/515454. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Nelson T. E. Malignant hyperthermia in dogs. J Am Vet Med Assoc. 1991 Mar 15;198(6):989–994. [PubMed] [Google Scholar]
- Ophoff R. A., Terwindt G. M., Vergouwe M. N., van Eijk R., Oefner P. J., Hoffman S. M., Lamerdin J. E., Mohrenweiser H. W., Bulman D. E., Ferrari M. Familial hemiplegic migraine and episodic ataxia type-2 are caused by mutations in the Ca2+ channel gene CACNL1A4. Cell. 1996 Nov 1;87(3):543–552. doi: 10.1016/s0092-8674(00)81373-2. [DOI] [PubMed] [Google Scholar]
- Parness J., Palnitkar S. S. Identification of dantrolene binding sites in porcine skeletal muscle sarcoplasmic reticulum. J Biol Chem. 1995 Aug 4;270(31):18465–18472. doi: 10.1074/jbc.270.31.18465. [DOI] [PubMed] [Google Scholar]
- Serfas K. D., Bose D., Patel L., Wrogemann K., Phillips M. S., MacLennan D. H., Greenberg C. R. Comparison of the segregation of the RYR1 C1840T mutation with segregation of the caffeine/halothane contracture test results for malignant hyperthermia susceptibility in a large Manitoba Mennonite family. Anesthesiology. 1996 Feb;84(2):322–329. doi: 10.1097/00000542-199602000-00009. [DOI] [PubMed] [Google Scholar]
- Sudbrak R., Golla A., Hogan K., Powers P., Gregg R., Du Chesne I., Lehmann-Horn F., Deufel T. Exclusion of malignant hyperthermia susceptibility (MHS) from a putative MHS2 locus on chromosome 17q and of the alpha 1, beta 1, and gamma subunits of the dihydropyridine receptor calcium channel as candidates for the molecular defect. Hum Mol Genet. 1993 Jul;2(7):857–862. doi: 10.1093/hmg/2.7.857. [DOI] [PubMed] [Google Scholar]
- Sudbrak R., Procaccio V., Klausnitzer M., Curran J. L., Monsieurs K., van Broeckhoven C., Ellis R., Heyetens L., Hartung E. J., Kozak-Ribbens G. Mapping of a further malignant hyperthermia susceptibility locus to chromosome 3q13.1. Am J Hum Genet. 1995 Mar;56(3):684–691. [PMC free article] [PubMed] [Google Scholar]
- Timerman A. P., Ogunbumni E., Freund E., Wiederrecht G., Marks A. R., Fleischer S. The calcium release channel of sarcoplasmic reticulum is modulated by FK-506-binding protein. Dissociation and reconstitution of FKBP-12 to the calcium release channel of skeletal muscle sarcoplasmic reticulum. J Biol Chem. 1993 Nov 5;268(31):22992–22999. [PubMed] [Google Scholar]